select semaglutide trial Long-term kidney outcomes of in obesity and cardiovascular disease in the Long-term weight loss effects of

Saxenda uses liraglutide, another GLP-1 receptor agonist, and is also approved specifically for weight loss

Those products have since been discontinued.

Youre already treating this demographicwhy send them elsewhere

64 4.2.1.1 RAPID ADOPTION OF GLP-1/INCRETIN INJECTABLES FOR OBESITY DRIVING DEMAND 4.2.1.2 BIOSIMILARS & ADC PIPELINE EXPANSION DRIVING STERILE INJECTABLE CONTRACT MANUFACTURING GROWTH 4.2.1.3 EU GMP ANNEX 1 COMPLIANCE & GLOBAL STERILE MANUFACTURING HARMONIZATION DRIVING CAPITAL INVESTMENT FOR ISOLATORS AND RABS 4.2.1.4 ROBOTICS, AUTOMATION, AND GLOVELESS ISOLATOR TECHNOLOGIES GAINING TRACTION 4.2.2.1 PRICE PRESSURE IN STERILE GENERICS AND HOSPITAL INJECTABLES 4.2.2.2 WORKFORCE CONSTRAINTS IN STERILE MANUFACTURING OPERATIONS 4.2.2.3 HIGH CAPEX AND LONG LEAD TIMES CONSTRAINING FILL-FINISH CAPACITY ADDITION 4.2.2.4 ORAL PEPTIDES AND ORAL GLP-1 DRUG DELIVERY RESTRAINING FILL-FINISH VOLUME GROWTH 4.2.3.1 GROWING DEMAND FOR CELL & GENE THERAPY/MRNA SMALL-BATCH MANUFACTURING 4.2.3.2 RISING NEED FOR AUTOMATED VISUAL INSPECTION AND CONTAINER CLOSURE INTEGRITY TESTING 4.2.3.3 INTEGRATION OF PREDICTIVE ANALYTICS 4.2.3.4 RADIOPHARMACEUTICAL AND THERANOSTIC DRUG PRODUCT FILL-FINISH EMERGING AS HIGH-GROWTH NICHE 4.2.4.1 SUSTAINABILITY PRESSURE AND HIGH ENERGY INTENSITY OF STERILE MANUFACTURING 4.3 UNMET NEEDS AND WHITE SPACES 4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES 4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 5 INDUSTRY TRENDS Navigate shifting industry dynamics with insights into competitive pressures and evolving manufacturing trends

Currently, Retatrutide is not FDA-approved for human use and can only be studied in lab environments and for research purposes